Filing Flows › Editas Medicine (EDIT) › Q2 2026
Editas Medicine (EDIT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Editas Medicine (EDIT) reported revenue of $11.9M for the second quarter 2026 (Q2 2026), +232% from a year earlier and +320% from the quarter before. Operating margin was -156.0%, net loss $18.2M (153.3% of revenue).
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.9M | +320% | +232% |
| Operating profit | −$18.6M | — | — |
| Net earnings | −$18.2M | — | — |
| Operating cash flow | −$29.6M | — | — |
What changed
Revenue was $11.9M in Q2 2026, up 232% year over year and up 320% from the previous quarter.
Operating costs exceeded revenue by $18.6M, an operating margin of -156.0%. Total costs fell 45% while revenue rose 232%. The quarter ended with a net loss of $18.2M, narrower than the previous quarter's $25.0M loss.
Operating cash flow was −$29.6M. Non-cash charges added back $416K of depreciation and $2.2M of share-based compensation. Working capital and other items used $13.9M. Capital expenditures of $106K exceeded it, leaving free cash flow of −$29.7M.
Questions
What was Editas Medicine's revenue in the second quarter 2026?
Editas Medicine (EDIT) reported revenue of $11.9M for the second quarter 2026 (Q2 2026), +232% from a year earlier and +320% from the quarter before.
Was Editas Medicine profitable in the second quarter 2026?
Operating loss was $18.6M (-156.0% of revenue) and net loss $18.2M.
Source: Editas Medicine 10-Q on SEC EDGAR.